Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.

Click to view original post